A published cutoff can make a decision process more legible, but only if its conditions stay attached. SSA's HIV listings rule, published December 2, 2016, provides several adult pathways rather than one universal laboratory trigger. This December 4 weekend analysis asks what that structure makes predictable, without treating a regulatory threshold as an automatic benefit award. [2016-28843][2014-04124]

Under adult 14.11G, an absolute CD4 count below 200 cells per cubic millimeter or a CD4 percentage below 14 must be combined with body mass index below 18.5 or hemoglobin below 8.0 grams per deciliter. Measurements need not share a date. A separate pathway, 14.11F, uses an absolute count of 50 or less with its documentation requirements; the combined test cannot stand in for the whole listing. [2016-28843][2014-04124]

The February 2014 proposal adds another lesson about predictability: proposed evidence requirements can change. It contemplated definitive laboratory documentation, while the final text retained guidance for non-definitive documentation. The pair is one SSA rulemaking history, not independent evidence that administrative costs fell or claim outcomes became more certain. [2016-28843][2014-04124]

The revisions cover adult and child HIV listings and immune-disorder functional guidance and specify January 17, 2017 effectiveness. Clear criteria can identify the questions an adjudication must answer, but this text does not quantify processing costs, fiscal savings or additional awards. The useful analytical distinction is between a more explicit decision structure and proven economic results. Neither isolated numbers nor a summary of historical rules can determine an individual's case. [2016-28843][2014-04124]

Source documents

  1. Revised Medical Criteria for Evaluating Human Immunodeficiency Virus (HIV) Infection and for Evaluating Functional Limitations in Immune System Disordershttps://www.govinfo.gov/content/pkg/FR-2016-12-02/html/2016-28843.htm
  2. Revised Medical Criteria for Evaluating Human Immunodeficiency Virus (HIV) Infection and for Evaluating Functional Limitations in Immune System Disordershttps://www.govinfo.gov/content/pkg/FR-2014-02-26/html/2014-04124.htm